Sequana Medical Announces the Completion of alfapump Implantations in POSEIDON, the North American Pivotal alfapump Study morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
Reporting of primary endpoint on track for Q4 2022FDA regulatory submission on track for mid-202370% survival of POSEIDON Roll-In patients at one year.
Anteris Technologies Ltd partners with medtech heavyweights for FDA early feasibility study proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
Sequana Medical NV
(Euronext Brussels: SEQUA, the Company or Sequana Medical ), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces positive results from the second interim analysis of POSEIDON, the North American pivotal study of the
alfapump for the treatment of recurrent or refractory ascites due to liver cirrhosis. These interim data from 26 patients in the Roll-In Cohort are in line with the previous interim data
ii, including positive outcomes against all primary endpoints of the study and a rapid and persistent clinically important improvement in quality of life measures.